Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on ESPR. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Price Performance

Shares of ESPR opened at $2.57 on Wednesday. The business has a 50-day simple moving average of $2.06 and a two-hundred day simple moving average of $2.16. The stock has a market cap of $506.39 million, a price-to-earnings ratio of -4.02 and a beta of 0.96. Esperion Therapeutics has a 52 week low of $1.16 and a 52 week high of $3.40.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently modified their holdings of the stock. BOKF NA bought a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $28,000. National Bank of Canada FI lifted its stake in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $44,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.